Region — International. Neutral scientific reference — not offered for sale here.
Research reference — not for sale
Orforglipron
Blead outcome
Weight loss (obesity)
grades vary by outcome ↓
Small molecule (non-peptide)
also called — orforglipron (or-for-GLIP-ron) · Lilly code LY3502970 · Chugai code OWL833
metabolicobesity / weighttype-2 diabetes (investigational)
Reference entry — NOT a sellable lane, NOT yet approved. Potentially the most consequential drug in this whole register — not because it's the strongest, but because it's the first oral small-molecule GLP-1, which could solve the class's cost-and-supply problem. NDA for obesity submitted Dec 2025. No dosing published here.
In brief
Orforglipron is the first oral small-molecule GLP-1 — a non-peptide pill, taken anytime without food/water restrictions, that in Phase 3 delivered semaglutide-level weight loss (~11–12%) and solid glycemic control. Its significance is less about the size of the effect than about manufacturing and access: a cheaply mass-produced oral GLP-1 that Lilly says it can supply worldwide without constraint. Lilly filed the obesity NDA in December 2025; it is not yet approved.
Legal standing, by region
- Everywhere — investigational, not approved. Obesity NDA submitted to the FDA (Dec 2025); T2D filing expected 2026. A potential 2026 approval would make it the first oral small-molecule GLP-1.
- Gray market: because it is a small molecule (easier to synthesise than a peptide), unregulated "research orforglipron" copies may proliferate faster than peptide knock-offs — and are just as unapproved and unverified.
- Sport: GLP-1 agonists are not currently on the WADA Prohibited List.
- This venture: not a sellable lane — an investigational drug.
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
OutcomeEvidence base · effectGrade
Weight loss (obesity)
Strong Phase 3 and FDA-filed, but not yet approved; efficacy is semaglutide-level, not tirzepatide-level
Phase 3 ATTAIN-1 (NEJM 2025, ~11–12%); NDA filed Dec 2025 · Meaningful; semaglutide-like
BType-2 diabetes glycemic control
Phase 3 complete/near-complete; T2D filing 2026; not yet approved
Phase 3 ACHIEVE programme (5 trials, superior A1C; NEJM 2025) · Robust, foundational
BWeight maintenance after injectables
First-of-its-kind; topline
ATTAIN-MAINTAIN (Dec 2025) · Maintained (switch from Wegovy/Zepbound)
BManufacturing / access advantage
The reason it may matter more than its weight-loss number
Small-molecule chemistry · Cheap, scalable, no cold chain, no food/water ritual
—Safety
Class-typical GI effects; investigational
Phase 3 (GI-predominant) · Consistent with the GLP-1 class
—Disclosure
Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.
Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.
Evidence changes
Get notified if this changes
We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for Orforglipron changes - nothing else.
Identity
an investigational, once-daily small-molecule (non-peptide) oral GLP-1 receptor agonist — and, critically, one that can be taken any time of day with no food or water restrictions. Discovered by Chugai Pharmaceutical (Japan) and licensed by Lilly in 2018; the two published its preclinical pharmacology together.
Mechanism (as proposed)
a small-molecule agonist of the GLP-1 receptor (with biased/partial-agonist pharmacology distinct from the peptide full agonists) → the familiar GLP-1 effects (glucose-dependent insulin, glucagon suppression, slowed gastric emptying, reduced appetite). The novelty is not the target but the chemistry — a non-peptide that survives oral dosing without absorption enhancers or a dosing ritual, and that can be manufactured like a conventional tablet.
Chemical identifiers
Cross-reference identifiers for the authoritative external databases — not a recipe, and nothing about how to use it.
InChIKeyUSUWIEBBBWHKNI-KHIFEHGGSA-N
SMILESC[C@H]1C[C@]1(C2=NOC(=O)N2)N3C4=C(C=C(C=C4)[C@H]5CCOC(C5)(C)C)C=C3C(=O)N6CCC7=NN(C(=C7[C@@H]6C)N8C=CN(C8=O)C9=C(C1=C(C=C9)N(N=C1)C)F)C1=CC(=C(C(=C1)C)F)C
UNII7ZW40D021M
via PubChem exact-name match (Orforglipron) · high confidence
Sources — 3 cited
01Eli Lilly — ACHIEVE-1 (NEJM, 2025); ATTAIN-1 (NEJM, Sept 2025); ATTAIN-MAINTAIN topline (Dec 2025); ACHIEVE-2/-5 (Oct 2025); head-to-head vs oral semaglutide.
02Chugai / Lilly — preclinical pharmacology of orforglipron (OWL833 / LY3502970).
03Lilly — obesity NDA submission and Commissioner's National Priority Voucher (Dec 2025).
Updated 2026-07-13 (fast-moving — re-check the FDA obesity decision and T2D filing)
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
VallydiaA neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.
Region — International
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.